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treated with statins tend to present less (44%) asymptomatic PAD than other patients 
(OR 0.56; 95%CI 0.30–1.05;p  0.07). Seventy-four percent of patients were 
aware of their CV risk, and smoking, high cholesterol, overweight and hypertension 
were identiﬁed by patients as the most important factors increasing the risk on 
CV disease. CONCLUSIONS: Asymptomatic PAD in subjects without CVD but 
at moderate risk was less prevalent in Belgium than in the other European countries, 
but was still signiﬁcantly correlated with classical CVD risk factors, especially 
smoking, hypertension, lipid proﬁle and age. It could be advisable to identify patients 
with such risk factors through ABI measurement and treat them accordingly as high 
risk individuals.
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OBJECTIVES: To compare 5-year cardiovascular (CV) event reduction between 
patients treated with generic simvastatin therapy (ST) and niacin extended-release 
[NER]  simvastatin (NER/S) combination therapy among primary and secondary risk 
patients from a managed care organization’s perspective. METHODS: Two hypotheti-
cal managed care formularies, each consisting of 1,000,000 primary and secondary 
risk patients were modeled over a ﬁve year time horizon: a current formulary where 
all patients were treated with ST and a revised formulary where all the patients were 
treated with NER/S. Study patients with sub-optimal LDL-C, HDL-C, and/or TG at 
baseline were sampled from the HealthCore Integrated Research Database between 
January 1, 2000 and February 28, 2005. Package insert efﬁcacy of lipid medications 
in each formulary was applied to the study population. Post-treatment lipid values 
were evaluated according to U.S. lipid guidelines. Incremental reduction in CV events 
[myocardial infarction (MI), peripheral vascular disease (PVD), and stroke] among 
NER/S treated patients versus ST patients was estimated. Market share of NER/S over 
ﬁve years was assumed to be 1.5%. RESULTS: A total of 529,620 study patients were 
identiﬁed, having a mean age of 54 o 11 years, 45% female, and Deyo-Chrlson 
comorbidity score of 0.38 o 0.62. Patients treated with NER/S therapy demonstrated 
an incremental reduction of 1,515 CV events (27,218 vs. 28,733) over 5 years as 
compared to ST. Incremental reduction in stroke events in the same period were 
found to be 564 (10,144 vs. 10,708), MI events reduced by 631 (11,341 vs. 11,972), 
while PVD events reduced by 319 (5,733 vs. 6,052). CONCLUSIONS: Treatment 
with NER/S among primary and secondary risk dyslipidemia patients was associated 
with 5-year reductions in CV events compared to ST treated patients. Further studies 
assessing the addition of NER to ST or switching ST treated patients to NER/S therapy 
on clinical and economic outcomes are needed.
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OBJECTIVES: There is little evidence to compare effectiveness of individual 
Angiotensin Receptor Blockers (ARBs) in patients with chronic heart failure (CHF). 
This study compared four ARBs in reducing risk of mortality in everyday clinical 
practice. METHODS: A retrospective analysis was conducted on a national sample 
of patients diagnosed with CHF from October 1, 1996 to September 30, 2002 
identiﬁed from VA Electronic Medical Records, with supplemental clinical data 
obtained from chart review. After excluding patients with exposure to ARBs 
within the previous six months, four treatment groups were deﬁned based on 
initial use of candesartan, valsartan, losartan, and irbesartan between the index 
date (October 1, 2000) and the study end date (September 30, 2002). Time to death 
was measured concurrently during that period. A marginal structural model (MSM) 
controlled for sociodemographic factors, comorbidities, co medications, disease 
severity (left ventricular ejection fraction), and potential time-varying confounding 
affected by previous treatment (hospitalization). Propensity scores derived from a 
multinomial logistic regression were used as inverse probability of treatment weights 
(IPTW) in a generalized estimating equation to estimate causal effects. Results of MSM 
were compared to estimates obtained from traditional Cox regression models 
RESULTS: Among the 1,536 patients identiﬁed on ARB therapy, irbesartan was 
most frequently used (55.21%), followed by losartan (21.74%), candesartan(15.23%) 
and valsartan (7.81%). Adjusted hazard ratios from Cox regression found Candesar-
tan to reduce risk of mortality compared with Losartan (HR  0.60, 95% CI 0.37–
0.96). After adjusting for time-varying hospitalization in MSM utilizing IPTW, 
candesartan was found not signiﬁcant (OR  0.79, 95% CI  0.42–1.50). Irbesartan 
and valsartan were found to have similar effectiveness compared to losartan in both 
analyses. CONCLUSIONS: Effectiveness of ARBs in reducing mortality did not differ 
in patients with CHF in everyday clinical practice. Marginal structural models can be 
used to compare the effectiveness of multiple treatment groups and may improve 
risk-adjustment.
PCV11
UNDERSTANDING THE IMPACT OF STATIN TITRATION;  
A MODELLING APPROACH
Gray AM1, Thompson R2, Ong S3
1Health Economics Research Centre, Oxford, UK, 2Pﬁzer, Tadworth, Surrey, UK, 3Pﬁzer Ltd, 
Tadworth, Surrey, UK
OBJECTIVES: Statin therapy has established cardiovascular beneﬁts. Clinical guide-
lines set target cholesterol levels for populations at different risk levels. Treatment 
strategies include initial high-dose or conventional-dose statin followed by titration of 
patients failing to reach target. Empirical data on dose titration are scarce, but this 
model simulates potential cholesterol reductions for different populations, therapies 
and titration steps. METHODS: Patient-level cholesterol values before statin therapy, 
obtained from a large UK primary care database, were grouped into four patient 
groups in 0.5 mmol/L bands from  1–10: 1) no CVD or diabetes; 2) CVD, no dia-
betes; 3) diabetes, no CVD; 4) diabetes and CVD. Dose efﬁcacy studies enabled cal-
culation of percentage reductions in cholesterol from speciﬁed therapies in each band, 
variance, and the corresponding probability of reaching a speciﬁed target. For patients 
failing to reach target, the next higher statin dose was applied to the starting choles-
terol value. Mean cholesterol values of those above/below target were calculated and 
inserted into a lifetime, cardiovascular outcomes, Excel-based model using Framing-
ham risk equations and baseline parameters from statin clinical trials. RESULTS: For 
the 4 population groups, with a mean cholesterol reduction of 30% (SD 10%), propor-
tions reaching a 4 mmol/L target in one step were: 1) 24%; 2) 35%; 3) 40%; and 4) 
45%. Patients above target had two further titrations, each higher-dose therapy reduc-
ing cholesterol by a further 5%, with proportions increasing to 49%, 63%, 68% and 
71% respectively. Based on these proportions and using Framingham risk equations, 
corresponding 10-year CVD event rates were estimated as 27%, 42%, 29% and 55% 
for one-step therapy, and 23%, 39%, 26% and 52% following titration. CONCLU-
SIONS: Titration models provide insights about the impact of different therapy strate-
gies on cardiovascular outcomes for different population groups. The addition of cost 
data enables the cost-effectiveness of competing statin strategies to be estimated.
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OBJECTIVES: To analyze the percentage of patients treated with anti-hypertensive 
medication in mono or dual therapy that experienced a CV event. METHODS: A 
retrospective study of the Southwestern Ontario database which contains chart-
abstracted information from primary health care facilities in Ontario, Canada was 
performed. Patients with hypertension were identiﬁed as those with a recorded Blood 
Pressure (BP) exceeding 140/90 mmHg, chart entry of a diagnosis of hypertension, or 
use of anti-hypertensive medication. Patients treated either in mono or dual therapy 
with angiotensin II receptor blockers (ARBs), ACE Inhibitors (ACEIs) and Calcium 
Channel Blockers (CCBs) were included. The number of patients who experienced at 
least one CV event from 2003 to 2008 was recorded. CV events are stroke, myocardial 
infarction, congestive heart failure, peripheral vascular disease, coronary heart disease, 
atrial ﬁbrillation or transient cerebral ischemic attack. Due to the well known com-
parable safety proﬁle of the compounds, a safety analysis was not performed. 
RESULTS: A total of 53,064 patients treated with an ARB, ACEI or CCB in mono 
or dual therapy were identiﬁed. The proportions of treated patients who experienced 
a CV event were 4.3% on ARBs compared to 7.0% on ACEIs and 11.0% on CCBs. 
These differences were statistically signiﬁcant (p  0.001). Within the ARB class, the 
proportions of treated patients who experienced a CV event were 3.0% on irbesartan 
compared to 4.6% on losartan, 5.0% on valsartan and 5.0% on candesartan. These 
differences were statistically signiﬁcant (p  0.02). CONCLUSIONS: In patients 
treated in mono or dual therapy, those treated with an ARB experienced signiﬁcantly 
fewer CV events than those treated with an ACEI or a CCB. Amongst the ARB-treated 
patients, those treated with irbesartan as part of their therapy experienced signiﬁcantly 
less CV events than those treated with another ARB.
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OBJECTIVES: To compare the effectiveness of the most commonly prescribed statins 
in Brazil for the prevention of cardiovascular CV events, using indirect comparison 
meta-analysis. METHODS: A systematic review of the literature was conducted. 
Medline and the Cochrane Controlled Trials Register were searched for clinical 
trials that compared Pravastatin 40 mg, Simvastatin 40 mg or Atorvastatin 10 mg 
against control (placebo or usual care), for primary and secondary CV prevention. 
Full-texts of relevant abstracts were retrieved and evaluated in duplicate and indepen-
dently. Fixed-effect models were used for direct statin versus control comparisons, 
and the methodology described by Bucher et al. (1997) was used to derive indirect 
comparisons between statins. RESULTS: Eleven studies comparing Pravastatin 40 mg 
